Regeneron Pharmaceuticals stock (NASDAQ: REGN) is up 15% since the start of June, with sentiment beginning to shift on the name heading into earnings. Despite the bounce, holders of REGN are continuing to nurse declines of 10% YTD, setting up a potentially pivotal print for direction into the second half of the year.
The Nasdaq listed name is scheduled to report second-quarter 2026 earnings before the US market opens today with somewhat of an unusual backdrop. Markets are looking for revenue growth but a sharp drop in earnings per share.
The Street is looking for Regeneron to post earnings per share of US$10.20 for the second quarter, down more than 22% from US$12.89 in the prior-year period. Revenue is forecast at US$3.83 billion, representing 4.08% year-on-year growth.
What To Expect
The most immediate risk factor for the stock post-earnings is the ongoing litigation. Multiple law firms filed securities class actions against Regeneron and certain executives in mid-July, alleging the company misled investors about the viability of its Phase III Fianlimab-Libtayo clinical trial in non-small cell lung cancer.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
According to the complaints, Regeneron disclosed on 29 April 2026 during its Q1 earnings call that the study had been altered, expanding the number of patients eligible for analysis. On 15 May 2026, the company reportedly announced further modifications to the trial, triggering stock declines of 6.2% and 9.8% on those respective dates.
On the positive side, Regeneron announced a strategic collaboration with Telix Pharmaceuticals in late July. Telix disclosed it received a non-refundable payment of approximately US$40 million from Regeneron as part of a partnership to develop next-generation radiopharmaceutical therapies. Regeneron’s involvement in this emerging treatment area could provide a long-term growth angle, though the near-term financial impact is modest.
Regeneron’s flagship drug Eylea (aflibercept) remains a major revenue contributor, and any signs of market share erosion, pricing pressure, or competition from biosimilars would be material. The company’s newer products, including Dupixent (developed with Sanofi) and Libtayo, are also closely watched for growth trajectory.
Margin performance and cost discipline will be under scrutiny given the expected EPS decline. If the company can articulate a clear path back to earnings growth in the second half of 2026 or into 2027, that could support the stock. On the other hand, if the guidance implies a prolonged period of margin compression or elevated spending, the market may push the stock lower even if revenue meets expectations.
Analysts remain divided on Regeneron heading into the print. The wide EPS estimate range reflects uncertainty not just about Q2 results, but about the company’s earnings power and pipeline outlook over the next 12 to 24 months.
Options markets are pricing a move of ~6% in Regeneron shares following the print, setting the stage for a potential $40 move in either direction.
